Trisha Novy, PhD, is Vice President of Medical Affairs at Vaxcyte and a vaccine development and medical affairs leader with more than 15 years of experience spanning immunology research, clinical development, product launches, and lifecycle management across the biopharmaceutical industry. Throughout her career at Vaxcyte, Dynavax Technologies, Moderna, GSK, and Novartis Vaccines, she has contributed to the advancement of vaccines targeting major infectious diseases, including COVID-19, hepatitis B, meningococcal disease, and pneumococcal disease.
Her work focuses on bridging immunology, clinical research, and public health to support the successful development and implementation of vaccines. She is passionate about improving disease prevention through scientific innovation, evidence generation, and meaningful engagement with the global vaccine community. Dr. Novy holds a PhD in Immunology from Duke University and a BS in Biological Sciences from the University of California, Davis.